Fol­low­ing a host of tri­al flops, An­gion halts R&D work, search­es for ‘strate­gic al­ter­na­tives’

Af­ter scrap­ping a Phase II kid­ney dis­ease study last month, it ap­pears An­gion Bio­med­ica may be out of moves.

The Union­dale, NY-based biotech an­nounced Mon­day af­ter­noon that it would be look­ing in­to “strate­gic al­ter­na­tives” — sug­gest­ing a po­ten­tial merg­er, re­verse merg­er and sale or li­cens­ing of its can­di­dates as op­tions it would be ex­plor­ing. In the mean­time, An­gion will be shut­ter­ing its R&D work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER